Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 12012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritisReview · 2012 · 1,807 citations
2. 2Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structuRCT · 2010 · 417 citations
3. 3Interleukin‐6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease‐modifying antirheumatic drugs: The tocilizumab in combination with traditional disease‐modifying antirheumatic drug therapy studyBlinded Clinical Trial · 2008 · 866 citations
4. 4Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti–IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman diseaseClinical Trial · 2008 · 824 citations
5. 5Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptorReview · 2009 · 269 citations